| Literature DB >> 31152360 |
Adam Seccombe1, Lauren McCluskey2, Hannah Moorey3, Daniel Lasserson3, Elizabeth Sapey3.
Abstract
BACKGROUND: Fluid resuscitation is a widely used intervention that is mandated in the management of sepsis. While its use can be life-saving, its overuse is associated with harm. Despite this, the best means of assessing a need for fluid resuscitation in an acute medical setting is unclear.Entities:
Keywords: acute medicine; fluid assessment; fluid responsiveness; intravenous fluid; sepsis
Mesh:
Year: 2019 PMID: 31152360 PMCID: PMC6711941 DOI: 10.1007/s11606-019-05073-9
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 5.128
Study Selection Criteria
| Study design | Diagnostic test accuracy studies |
|---|---|
| Participants | Adults (aged ≥ 18 years) with sepsis of any severity or confirmed infection. Studies were excluded if they involved children, pregnant women, burns patients, trauma patients, perioperative patients, or patients who were mechanically ventilated. |
| Index test | Any history question, examination technique, or diagnostic test |
| Reference standard | Any |
| Target condition | Hypovolaemia or a need for fluid resuscitation |
Figure 1Flowchart of study selection. Legend: flowchart summarising study selection and inclusion processes in this systematic review, including the reasons for exclusion of all full-text articles that were reviewed.
Main Characteristics of Included Studies
| Author | Year | Setting | No. of patients | Patient population | Primary index test(s) | Additional index test(s) | Reference standard | Target condition | Hypovolaemia mentioned? |
|---|---|---|---|---|---|---|---|---|---|
| de Valk[ | 2014 | ED, Netherlands | 23* | Shock (SBP < 90, SBP > 40 less than normal, HR > 100, CRT > 2 s, or lactate > 2) | IVCCI | None | Rise in SBP after fluid bolus | Fluid responsiveness | Yes |
| Corl[ | 2017 | ED/ICU, USA | 55* | ACF (SBP < 90/MAP < 65 for > 30 min, UO < 0.5, HR > 120 for > 30 min, pH < 7.3, or lactate > 2) | IVCCI | Change in IVCCI after fluid and PLR, IVCDi/e | Rise in CI after fluid bolus | Fluid responsiveness | No |
| Muller[ | 2012 | ICU, France | 40 | ACF (MAP < 65, UO < 0.5, tachycardia, mottled skin, or lactate > 2) | IVCCI | E wave velocity, LVOT VTI, E/A ratio, E/Ea ratio | Rise in LVOT VTI after | Fluid responsiveness | No |
| Preau[ | 2017 | ICU, France | 90 | Sepsis and ACF (SBP < 90, SBP > 40 less than normal, UO < 0.5, HR > 100, or mottled skin) | IVCCI ± standardised respiration | IVCD, SVI | Rise in SVI after fluid bolus | Fluid responsiveness | Yes |
| Lanspa[ | 2013 | ED/ICU, USA | 14 | Sepsis and refractory hypotension (SBP < 90 after > 20 mL/kg of IV fluid) | IVVCI, AoVV, and SVV | None | Rise in CI after fluid bolus | Fluid responsiveness | No |
| Abodorra[ | 2014 | ICU, Egypt | 40 | Sepsis and ACF (undefined) | IVCCI (after fluid bolus) | Change in IVCCI after fluid | Rise in LVOT VTI after fluid bolus | Fluid responsiveness | No |
| Dutta[ | 2014 | ED/ICU, India | 116 | Sepsis and hypotension (undefined) | Change in SV after PLR | None | Rise in SV after fluid bolus | Fluid responsiveness | Yes |
| Klarer[ | 2010 | ICU, Switzerland | 27 | Hypotension (MAP < 60 mmHg) and/or reduced CI (CI < 2.7 L/min/m2) | Change in CI, SVI, and MAP after PLR | None | Rise in CI after fluid bolus | Fluid responsiveness | No |
| Preau[ | 2010 | ICU, France | 34 | Sepsis or acute pancreatitis and ACF (SBP < 90, SBP > 40 less than normal, UO < 0.5, HR > 100, or mottled skin) | Change in SV, PP, and VF after PLR | None | Rise in SV after fluid bolus | Fluid responsiveness | Yes |
| Soubrier[ | 2007 | ICU, France | 32 | Haemodynamic instability (SBP < 90, MAP < 75, SBP > 40 less than normal, UO < 0.5 over 3 h, HR > 100, or mottled skin) | PPV and SBPV ± standardised respiration | None | Rise in CI after fluid bolus | Fluid responsiveness | Yes |
| Preau[ | 2012 | ICU, France | 23 | ACF (SBP < 90, SBP > 40 less than normal, UO < 0.5 for > 1 h, HR > 100, or mottled skin) | PPV and VFV ± standardised respiration | None | Rise in SV after fluid bolus | Fluid responsiveness | No |
| Jung[ | 2012 | ED, South Korea | 26 | Sepsis and hypotension (SBP < 90, MAP < 70, SBP > 40 less than normal in the absence of another cause) | FTc | CVP, IVCD | Rise in SV after fluid bolus | Fluid responsiveness | No |
| Keller[ | 2009 | ICU, USA | 44 | Any admission to ICU with a plan to insert a CVC | IJV aspect ratio | None | CVP < 8 mmHg | Fluid responsiveness | No |
| Soliman[ | 2017 | ICU, Egypt | 30 | Sepsis and hypotension (MAP < 65) or impaired tissue perfusion (lactate > 4) | Change in CO after fluid | None | MAP > 65 and lactate < 4 | Fluid responsiveness | No |
Summary of the 14 included studies and illustrating the wide heterogeneity. Primary index tests are those mentioned in the study’s aim.
ACF acute circulatory failure, AoVV aortic velocity variation, CI cardiac index, CO cardiac output, CRT capillary refill time, CVP central venous pressure, ED emergency department, FTc corrected flow time, HR heart rate, ICU intensive care unit, IJV internal jugular vein, IVCCI inferior vena cava collapsibility index, IVCDi/e end-inspiratory/expiratory inferior vena cava diameter, LVOT VTI left ventricular outflow tract velocity time integral, MAP mean arterial pressure, PLR passive leg raise, PP pulse pressure, PPV pulse pressure variation, SBP systolic blood pressure, SBPV systolic blood pressure variation, SV stroke volume, SVI stroke volume index, SVV stroke volume variation, UO urine output, VF femoral artery velocity, VFV femoral artery velocity variation
*Individual patient data
Main Patient Characteristics
| Author | Year | Male (%) | Age (years) | MAP (mmHg) | HR (bpm) | Diagnoses | Additional treatment (e.g. inotropes) | Preceding IV fluid (L) |
|---|---|---|---|---|---|---|---|---|
| de Valk[ | 2014 | 23 (48) | 55 ± 18 | 75 ± 15 | 117 ± 8 | Sepsis (100) | – | M 100 (Q 0–325) |
| Corl[ | 2017 | 23 (42) | 68 ± 19 | 99 ± 19 | 115 ± 30 | Sepsis (100) | Vasopressors (58) | M 4000 (Q 3350–6000) |
| Muller[ | 2012 | – | M 63 (5P 56, 95P 70) | M 71 (5P 66, 95P 77) | M 101 (5P 91, 95P 116) | Sepsis (60), bleeding (28), dehydration (13) | – | – |
| Preau[ | 2017 | 58 (64) | 55 ± 29 | Unknown | 102 ± 33 | Sepsis (100) | Vasopressors (16) | (within 24 h) M 1000 (0–2500) |
| Lanspa[ | 2013 | 5 (36) | M 62 (Q 46–81) | M 65 (Q 61–70) | M 102 (Q 80–112) | Sepsis (100) | Vasopressors (57) | M 4600 (Q 3000–5900) |
| Abodorra[ | 2014 | – | 54 ± 14 | 58 ± 12 | 108 ± 12 | Sepsis (100) | – | – |
| Dutta[ | 2014 | – | – | Unknown | Unknown | Sepsis (100) | – | – |
| Klarer[ | 2010 | – | M 60 (R 29–82) | M 61 (R 48–104) | M 104 (R 53–145) | Sepsis (52), heart failure (19), respiratory failure (15), other (14) | Vasopressors/inotropes (100) | – |
| Preau[ | 2010 | 19 (56) | 53 ± 19 | 77 ± 14 | 101 ± 22 | Sepsis (82), acute pancreatitis (18) | Vasopressors (18) | – |
| Soubrier[ | 2007 | 9 (28) | 61 ± 13 | 89 ± 14 | 103 ± 16 | Sepsis (13), pneumonia (75), haematological disease (3), trauma (6), abdominal surgery (3) | Vasopressors (9) | 25% received IV fluid in preceding 24 h |
| Preau[ | 2012 | 16 (70) | 50 ± 5 | 79 ± 11 | 104 ± 19 | Sepsis (87), acute pancreatitis (13) | – | – |
| Jung[ | 2012 | 17 (65) | M 74 (Q 58–83) | M 57 (Q 50–66) | 94 (83–114) | Sepsis (100) | No | – |
| Keller[ | 2009 | 22 (50) | 66 ± 14 | 67 ± 12 | 92 ± 22 | Sepsis (46), GI bleed (14), heart failure (9), not recorded (32) | – | – |
| Soliman[ | 2017 | 43.3 | 48 ± 20 | 53 ± 8 | – | Sepsis (100) | Vasopressors (not recorded) | – |
Summary of the patient characteristics for the included studies. “–” means data not available. Data are presented as means ± SD or as medians (indicated by “M”) with a measure of spread in brackets (preceded by “Q” if quartiles, “R” if range, and “5P” or “95P” if 5th and 95th percentiles respectively). Number of patients, names of diagnoses, and use of vasopressors are presented with percentages in parenthesis.
*Individual patient data
Summary of Reference Standards
| Author | Year | Met reference standard (%) | Measurement | Fluid bolus | ||||
|---|---|---|---|---|---|---|---|---|
| Parameter | Threshold rise (%) | Measurement tool | Volume | Fluid type | Rate (min) | |||
| de Valk[ | 2014 | 17.4 | Systolic blood pressure | > 10 mmHg | NIBP | 500 mL | 0.9% saline | 15 |
| Corl[ | 2017 | 56.4 | Cardiac index | > 10 | Bioreactance | 500 mL | 0.9% saline | Pressure bag |
| Muller[ | 2012 | 50 | LVOT VTI | > 15 | Echocardiography | 500 mL | 6% starch | 15 |
| Preau[ | 2017 | 55.6 | Stroke volume index | > 10 | Echocardiography | 500 mL | 4% gelatine | 30 |
| Lanspa[ | 2013 | 35.7 | Cardiac index | > 15 | Echocardiography | 10 mL/kg | Crystalloid | < 20 |
| Abodorra[ | 2014 | 50 | LVOT VTI | > 15 | Echocardiography | 500 mL | Not recorded | 15 |
| Dutta[ | 2014 | 62.9 | Stroke volume | > 10 | Echocardiography | 30 mL/kg | Crystalloid | Not recorded |
| Klarer[ | 2010 | Not recorded | Cardiac index | > 15 | Pulse contour analysis | 500 mL | 0.9% saline | 15 |
| Preau[ | 2010 | 41.1 | Stroke volume | > 15 | Echocardiography | 500 mL | 6% starch | 30 |
| Soubrier[ | 2007 | 59.4 | Cardiac index | > 15 | Echocardiography | 500 mL | 6% starch | 20 |
| Preau[ | 2012 | 43.5 | Stroke volume | > 15 | Echocardiography | 500 mL | 6% starch | 30 |
| Jung[ | 2012 | 65.4 | Stroke volume | > 10 | Oesophageal Doppler | 7 mL/kg | 6% starch | 30 |
| Keller[ | 2009 | 59.1 | Central venous pressure < 8 mmHg via central venous catheter | N/A—static test | ||||
| Soliman[ | 2017 | 33.3 | MAP < 65 mmHg or lactate < 4 mmol/L (measurement tool unclear) | N/A—static test | ||||
Summary of the reference standards used by each study described according to the method of measuring the physiological parameter and, if a dynamic assessment tool was used, the means by which the fluid bolus was given.
LVOT VTI left ventricular outflow tract velocity time integral, NIBP non-invasive blood pressure
Summary of Studied Index Tests
| Category of index test | Author | Year | Primary index tests (measurement tool) | Threshold | AUROC | Sn | Sp | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|
| Inferior vena cava | de Valk[ | 2014 | IVCCI (US) | ≥ 36.5% | 0.68 (0.37–0.98) | 75 | 57.9 | 27.3 | 97.7 |
| Corl[ | 2017 | IVCCI (US) | ≥ 25% | 0.82 (0.68–0.95) | 83.9 | 79.2 | 83.9 | 79.2 | |
| Muller[ | 2012 | IVCCI (US) | ≥ 40% | 0.77 (0.60–0.88) | 70 | 80 | 77.8 | 72.7 | |
| Preau[ | 2017 | IVCCI (US) | ≥ 48% | 0.82 (0.73–0.91) | 76 | 88 | 88 | 75 | |
| IVCCI with standardised respiration (US) | ≥ 31% | 0.89 (0.82–0.97) | 84 | 90 | 91 | 82 | |||
| Lanspa[ | 2013 | IVCCI (US) | ≥ 15% | 0.83 (0.58–1.00) | 100 | 67 | 62 | 100 | |
| Abodorra[ | 2014 | IVCCI after 100 mL (US) | > 45% | 0.91 | 90 | 65 | 72 | 88.7 | |
| PLR | Dutta[ | 2014 | Change in SV (Echo) | ≥ 15% | – | 87.7 | 100 | 100 | 82.7 |
| Klarer[ | 2010 | Change in CI (PC) | > 15% | – | – | – | 50 | 86 | |
| Change in SVI (PC) | > 15% | – | – | – | 20 | 77 | |||
| Change in MAP (PC) | > 10% | – | – | – | 12 | 80 | |||
| Preau[ | 2010 | Change in SV (Echo) | ≥ 10% | 0.94 (0.90–0.98) | 86 | 90 | 86 | 90 | |
| Change in PP (PC) | ≥ 9% | 0.86 (0.78–0.94) | 79 | 85 | 79 | 85 | |||
| Change in VF (Echo) | ≥ 8% | 0.93 (0.89–0.97) | 86 | 80 | 75 | 89 | |||
| Respiration | Lanspa[ | 2013 | AoVV (Echo) | ≥ 25% | 0.67 (0.32–1.00) | 75 | 66.7 | 50 | 85.7 |
| SVV (PC) | ≥ 17% | 0.92 (0.73–1.00) | 60 | 100 | 100 | 81.8 | |||
| Soubrier[ | 2007 | PPVa (PC) | ≥ 12% | 0.81 (0.73–0.89) | 63 | 92 | 92 | 63 | |
| SBPV (PC) | ≥ 9% | 0.82 (0.74–0.90) | 47 | 92 | 90 | 54 | |||
| PPVa with standardised respiration (PC) | ≥ 33% | 0.72 (0.63–0.81) | 21 | 92 | 80 | 44 | |||
| SBPV with standardised respiration (PC) | ≥ 30% | 0.69 (0.59–0.79) | 26 | 92 | 80 | 83 | |||
| Preau[ | 2012 | PPVa (PC) | ≥ 10% | 0.71 (0.59–0.83) | 60 | 100 | 100 | 76 | |
| VFV (US) | ≥ 10% | 0.74 (0.63–0.85) | 60 | 100 | 100 | 76 | |||
| PPVa with standardised respiration (PC) | ≥ 12% | 0.95 (0.90–1.00) | 90 | 100 | 100 | 93 | |||
| VFV with standardised respiration (US) | ≥ 12% | 0.95 (0.90–1.00) | 90 | 100 | 100 | 93 | |||
| Static | Jung[ | 2012 | FTc (oesophageal Doppler) | < 301 ms | 0.87 (0.71–0.98) | 88.2 | 88.8 | 93.7 | 79.9 |
| Keller[ | 2009 | IJV aspect ratio (US) | < 0.83 | 0.84 (0.72–0.96) | 78 | 77 | 83 | 71 | |
| Fluid | Soliman[ | 2017 | Change in CO (bioimpedance) after 30 mL/kg 0.9% saline over 2 h | > 12.5% | 0.9 | 90 | 70 | 80 | 90 |
Summary of the primary index tests for included studies. “–” means data not available.
AoVV aortic velocity variation, AUROC area under the curve of the receiver operating characteristic, CI cardiac index, CO cardiac output, FTc corrected flow time, IJV internal jugular vein, IVCCI inferior vena cava collapsibility index, MAP mean arterial pressure, NPV negative predictive value, PC pulse contour analysis, PLR passive leg raise, PP pulse pressure, PPV positive predictive value, PPVa pulse pressure variation, SBP systolic blood pressure, SBPV systolic blood pressure variation, Sn sensitivity, Sp specificity, SV stroke volume, SVI stroke volume index, SVV stroke volume variation, US ultrasound, VF femoral artery velocity, VFV femoral artery velocity variation
*Individual patient data
Figure 2Risk of bias assessment. Legend: table summarising a risk of bias assessment performed using a modified version of QUADAS-2. [23] “+”: low risk of bias; “?”: unclear risk of bias; “-”: high risk of bias.